ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
ExcelFemale
HRT in Women
Study Review: Effect of Testosterone Creams in Women with Low Sex Drive
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 57910" data-attributes="member: 3"><p><strong>Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis.</strong></p><p></p><p>Achilli C, et al. Fertil Steril. 2016.</p><p></p><p>Authors</p><p></p><p>Achilli C1, Pundir J2, Ramanathan P1, Sabatini L1, Hamoda H3, Panay N4.</p><p></p><p>Author information</p><p>1Centre for Reproductive Medicine, St. Bartholomew's Hospital, London, United Kingdom.</p><p>2Centre for Reproductive Medicine, St. Bartholomew's Hospital, London, United Kingdom. Electronic address: <a href="mailto:jyotsnapundir@yahoo.com">jyotsnapundir@yahoo.com</a>.</p><p>3King's College Hospital, London, United Kingdom.</p><p>4Queen Charlotte's and Chelsea Hospital, London, United Kingdom.</p><p>Citation</p><p></p><p>Fertil Steril. 2016 Dec 1. pii: S0015-0282(16)62951-5. doi: 10.1016/j.fertnstert.2016.10.028. [Epub ahead of print]</p><p></p><p>Abstract</p><p></p><p>OBJECTIVE: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopausal women for the treatment of hypoactive sexual desire disorder (HSDD).</p><p></p><p>DESIGN: Systematic reviews and meta-analysis.</p><p></p><p>SETTING: Not applicable.</p><p></p><p>PATIENT(S): Seven randomized controlled trials enrolled 3,035 participants; 1,350 women were randomized to treatment with T patch, and 1,379 women were randomized to placebo.</p><p></p><p>INTERVENTION(S): None.</p><p></p><p>MAIN OUTCOME MEASURE(S): Primary outcome: satisfying sexual episodes.</p><p></p><p>SECONDARY OUTCOMES: sexual activity, orgasm, Profile of Female Sexual Function domains (desire), personal distress score, adverse events, acne, increased hair growth, facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction, total adverse events, serious adverse events, withdrawal from study, and follow-up rate.</p><p></p><p>RESULT(S): <strong>The T group had significantly more satisfying sexual episodes, sexual activity, orgasms, desire, significant change in Personal Distress Scale score, androgenic adverse events, acne, and hair growth compared with the placebo group. There was no significant difference between the two groups in increase in facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction to the patch, total adverse events, serious adverse events, reasons for withdrawal from the study, and the number of women who completed the study.</strong></p><p></p><p>CONCLUSION(S): The short-term efficacy in terms of improvement of sexual function and safety of transdermal T in naturally and surgically menopausal women affected by HSDD either on or not on estrogen progestin hormone therapy is evident from this systematic review.<strong> The use of transdermal T is associated with increase in androgenic adverse events such as acne but is not associated with any serious adverse events.</strong></p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 57910, member: 3"] [B]Efficacy and safety of transdermal testosterone in postmenopausal women with hypoactive sexual desire disorder: a systematic review and meta-analysis.[/B] Achilli C, et al. Fertil Steril. 2016. Authors Achilli C1, Pundir J2, Ramanathan P1, Sabatini L1, Hamoda H3, Panay N4. Author information 1Centre for Reproductive Medicine, St. Bartholomew's Hospital, London, United Kingdom. 2Centre for Reproductive Medicine, St. Bartholomew's Hospital, London, United Kingdom. Electronic address: [email]jyotsnapundir@yahoo.com[/email]. 3King's College Hospital, London, United Kingdom. 4Queen Charlotte's and Chelsea Hospital, London, United Kingdom. Citation Fertil Steril. 2016 Dec 1. pii: S0015-0282(16)62951-5. doi: 10.1016/j.fertnstert.2016.10.028. [Epub ahead of print] Abstract OBJECTIVE: To systematically review and summarize the existing evidence related to the efficacy and safety of transdermal T in postmenopausal women for the treatment of hypoactive sexual desire disorder (HSDD). DESIGN: Systematic reviews and meta-analysis. SETTING: Not applicable. PATIENT(S): Seven randomized controlled trials enrolled 3,035 participants; 1,350 women were randomized to treatment with T patch, and 1,379 women were randomized to placebo. INTERVENTION(S): None. MAIN OUTCOME MEASURE(S): Primary outcome: satisfying sexual episodes. SECONDARY OUTCOMES: sexual activity, orgasm, Profile of Female Sexual Function domains (desire), personal distress score, adverse events, acne, increased hair growth, facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction, total adverse events, serious adverse events, withdrawal from study, and follow-up rate. RESULT(S): [B]The T group had significantly more satisfying sexual episodes, sexual activity, orgasms, desire, significant change in Personal Distress Scale score, androgenic adverse events, acne, and hair growth compared with the placebo group. There was no significant difference between the two groups in increase in facial hair, alopecia, voice deepening, urinary symptoms, breast pain, headache, site reaction to the patch, total adverse events, serious adverse events, reasons for withdrawal from the study, and the number of women who completed the study.[/B] CONCLUSION(S): The short-term efficacy in terms of improvement of sexual function and safety of transdermal T in naturally and surgically menopausal women affected by HSDD either on or not on estrogen progestin hormone therapy is evident from this systematic review.[B] The use of transdermal T is associated with increase in androgenic adverse events such as acne but is not associated with any serious adverse events.[/B] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
ExcelFemale
HRT in Women
Study Review: Effect of Testosterone Creams in Women with Low Sex Drive
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top